HIV-1 Vaccine Development After STEP

被引：84

作者：

Barouch, Dan H. ^{[1
,2
]}

Korber, Bette ^{[3
,4
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Div Vaccine Res, Boston, MA 02115 USA

[2] Ragon Inst MGH MIT & Harvard, Boston, MA USA

[3] Los Alamos Natl Lab, Los Alamos, NM USA

[4] Santa Fe Inst, Santa Fe, NM 87545 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2010年 / 61卷

基金：

美国国家卫生研究院;

关键词：

HIV-1; viral diversity; antigen design; T cell vaccines; antibody vaccines; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; IMMUNE-RESPONSES; NEUTRALIZING ANTIBODIES; SUBTYPE-B; IMMUNOGENICITY EVALUATION; ENVELOPE GLYCOPROTEIN; VIRAL REPLICATION; LYMPHOCYTE ESCAPE; PHASE-1; SAFETY;

D O I：

10.1146/annurev.med.042508.093728

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Despite more than 2 5 years of concerted worldwide research, the development of a safe and effective HIV-1 vaccine remains elusive. Prototype antibody-based and T cell-based HIV-1 vaccines have failed to show efficacy in clinical trials to date. Next-generation HIV-1 vaccine candidates are in various stages of preclinical and clinical development, but key scientific obstacles pose major challenges for the field. Critical hurdles include the enormous global diversity of the virus and the challenges associated with generating broadly reactive neutralizing antibody and cellular immune responses. We review the current state of the HIV-1 vaccine field and outline strategies that are being explored to overcome these roadblocks.

引用

页码：153 / 167

页数：15

共 99 条

[1] Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D [J].

Abbink, Peter ;

Lemckert, Angelique A. C. ;

Ewald, Bonnie A. ;

Lynch, Diana M. ;

Denholtz, Matthew ;

Smits, Shirley ;

Holterman, Lennart ;

Damen, Irma ;

Vogels, Ronald ;

Thorner, Anna R. ;

O'Brien, Kara L. ;

Carville, Angela ;

Mansfield, Keith G. ;

Goudsmit, Jaap ;

Havenga, Menzo J. E. ;

Barouch, Dan H. .

JOURNAL OF VIROLOGY, 2007, 81 (09) :4654-4663

[2] Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants [J].

Abrahams, M. -R. ;

Anderson, J. A. ;

Giorgi, E. E. ;

Seoighe, C. ;

Mlisana, K. ;

Ping, L. -H. ;

Athreya, G. S. ;

Treurnicht, F. K. ;

Keele, B. F. ;

Wood, N. ;

Salazar-Gonzalez, J. F. ;

Bhattacharya, T. ;

Chu, H. ;

Hoffman, I. ;

Galvin, S. ;

Mapanje, C. ;

Kazembe, P. ;

Thebus, R. ;

Fiscus, S. ;

Hide, W. ;

Cohen, M. S. ;

Karim, S. Abdool ;

Haynes, B. F. ;

Shaw, G. M. ;

Hahn, B. H. ;

Korber, B. T. ;

Swanstrom, R. ;

Williamson, C. .

JOURNAL OF VIROLOGY, 2009, 83 (08) :3556-3567

[3] Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection [J].

Allen, TM ;

Altfeld, M ;

Yu, XG ;

O'Sullivan, KM ;

Lichterfeld, M ;

Le Gall, S ;

John, M ;

Mothe, BR ;

Lee, PK ;

Kalife, ET ;

Cohen, DE ;

Freedberg, KA ;

Strick, DA ;

Johnston, MN ;

Sette, A ;

Rosenberg, ES ;

Mallal, SA ;

Goulder, PJR ;

Brander, C ;

Walker, BD .

JOURNAL OF VIROLOGY, 2004, 78 (13) :7069-7078

[4] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].

Amara, RR ;

Villinger, F ;

Altman, JD ;

Lydy, SL ;

O'Neil, SP ;

Staprans, SI ;

Montefiori, DC ;

Xu, Y ;

Herndon, JG ;

Wyatt, LS ;

Candido, MA ;

Kozyr, NL ;

Earl, PL ;

Smith, JM ;

Ma, HL ;

Grimm, BD ;

Hulsey, ML ;

Miller, J ;

McClure, HM ;

McNicholl, JM ;

Moss, B ;

Robinson, HL .

SCIENCE, 2001, 292 (5514) :69-74

[5] Challenges in the development of an HIV-1 vaccine [J].

Barouch, Dan H. .

NATURE, 2008, 455 (7213) :613-619

[6] Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].

Barouch, DH ;

Pau, MG ;

Custers, JHHV ;

Koudstaal, W ;

Kostense, S ;

Havenga, MJE ;

Truitt, DM ;

Sumida, SM ;

Kishko, MG ;

Arthur, JC ;

Korioth-Schmitz, B ;

Newberg, MH ;

Gorgone, DA ;

Lifton, MA ;

Panicali, DL ;

Nabel, GJ ;

Letvin, NL ;

Goudsmit, J .

JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297

[7]

BAROUCH DH, 2009, KEYST S HIV VACC KEY

[8] Founder effects in the assessment of HIV polymorphisms and HLA allele associations [J].

Bhattacharya, Tanmoy ;

Daniels, Marcus ;

Heckerman, David ;

Foley, Brian ;

Frahm, Nicole ;

Kadie, Carl ;

Carlson, Jonathan ;

Yusim, Karina ;

McMahon, Ben ;

Gaschen, Brian ;

Mallal, Simon ;

Mullins, James I. ;

Nickle, David C. ;

Herbeck, Joshua ;

Rousseau, Christine ;

Learn, Gerald H. ;

Miura, Toshiyuki ;

Brander, Christian ;

Walker, Bruce ;

Korber, Bette .

SCIENCE, 2007, 315 (5818) :1583-1586

[9] Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C [J].

Binley, James M. ;

Lybarger, Elizabeth A. ;

Crooks, Emma T. ;

Seaman, Michael S. ;

Gray, Elin ;

Davis, Katie L. ;

Decker, Julie M. ;

Wycuff, Diane ;

Harris, Linda ;

Hawkins, Natalie ;

Wood, Blake ;

Nathe, Cory ;

Richman, Douglas ;

Tomaras, Georgia D. ;

Bibollet-Ruche, Frederic ;

Robinson, James E. ;

Morris, Lynn ;

Shaw, George M. ;

Montefiori, David C. ;

Mascola, John R. .

JOURNAL OF VIROLOGY, 2008, 82 (23) :11651-11668

[10] Microbial translocation is a cause of systemic immune activation in chronic HIV infection [J].

Brenchley, Jason M. ;

Price, David A. ;

Schacker, Timothy W. ;

Asher, Tedi E. ;

Silvestri, Guido ;

Rao, Srinivas ;

Kazzaz, Zachary ;

Bornstein, Ethan ;

Lambotte, Olivier ;

Altmann, Daniel ;

Blazar, Bruce R. ;

Rodriguez, Benigno ;

Teixeira-Johnson, Leia ;

Landay, Alan ;

Martin, Jeffrey N. ;

Hecht, Frederick M. ;

Picker, Louis J. ;

Lederman, Michael M. ;

Deeks, Steven G. ;

Douek, Daniel C. .

NATURE MEDICINE, 2006, 12 (12) :1365-1371

← 1 2 3 4 5 6 7 8 9 10 →